Cancer cells support their growth and proliferation by reprogramming their metabolism in
order to gain access to nutrients. Despite the heterogeneity in genetic mutations that lead to …

In last years several improvements have been made in the management of prostate cancer
(PCa). Androgen receptor (AR) is considered the main driver in PCa growth and progression …

Background The progression of prostate cancer to castration-resistant prostate cancer
(CRPC) is often a result of somatic alterations in the PI3K/Akt/mTOR (mammalian target of …

Resistance to docetaxel is a key problem in current prostate cancer management.
Sphingosine kinase 1 (SK1) and phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of …

Androgen deprivation therapy (ADT) is the mainstay treatment for advanced prostate cancer
(PC). Most patients eventually progress to a condition known as castration-resistant prostate …

Simple Summary Therapies that inhibit androgen receptor signaling induce cell death by
apoptosis in prostate epithelium and involution of non-malignant prostate gland, but are not …

Background Besides clinical stage and Gleason score, risk-stratification of prostate cancer in
the pretherapeutic setting mainly relies on the serum PSA level. Yet, this is associated with …

Background This phase II study was conducted to assess clinical efficacy of tasquinimod
maintenance therapy in patients with metastatic castrate-resistant prostate cancer not …

The HIF-1 signaling pathway plays an important role in the pathogenesis of cancer. Many
studies have explored the progression of prostate cancer (PCa) under hypoxic conditions …

Background Previous data suggests that co-targeting mammalian target of rapamycin and
angiogenic pathways may potentiate effects of cytotoxic chemotherapy. We studied …